Heather Curtis, DO
Otolaryngology/Facial Plastic Surgery · Hannibal, MONPI 1609244193
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $42,665 of the $57,327 with a category attached, or 74.4%. 29 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 57.0% of the total. 2025 is the largest year on record at $39,933, more than ten times the $46 reported in 2019.
Across 121 payments — averaging $473.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$33K
- Sanofi$24K
- Merck$131
- Aerin Medical Inc.$85
- Novartis$81
- Sanofi-aventis U.S. LLC$68
- plus $689 from 23 others
What the payments were for
- Consulting fees$8,57415%
- Speaking & faculty fees$42,66574%
- Travel & lodging$3,3986%
- Food & beverage$2,6225%
- Education$680%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 45 | $32,657 |
| Sanofi | 27 | $23,617 |
| Merck | 5 | $131 |
| Aerin Medical Inc. | 4 | $85 |
| Novartis | 4 | $81 |
| Sanofi-aventis U.S. LLC | 1 | $68 |
| Amgen | 4 | $66 |
| Johnson & Johnson | 4 | $63 |
| Taiho Oncology, Inc. | 3 | $52 |
| Medtronic | 2 | $46 |
| EMD Serono, Inc. | 2 | $43 |
| Optinose US, Inc. | 2 | $40 |
| Acclarent, Inc | 1 | $39 |
| AstraZeneca | 2 | $38 |
| Integra Lifesciences Corporation | 1 | $37 |
| Tempus AI, Inc | 1 | $28 |
| Alk-abello, Inc | 1 | $24 |
| Lilly USA, LLC | 1 | $22 |
| Seagen Inc. | 1 | $22 |
| Smith+Nephew | 1 | $22 |
| Cochlear Americas | 1 | $20 |
| Intersect ENT, Inc. | 1 | $18 |
| Greer Laboratories, Inc. | 1 | $18 |
| Sobi, Inc | 1 | $17 |
| GSK | 1 | $17 |
| Incyte Corporation | 1 | $16 |
| Stryker | 1 | $15 |
| Rigel Pharmaceuticals, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$59,715
How this compares
Too few otolaryngology/facial plastic surgery providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ipratropium Bromide | 53 | $1,292 |
| Prednisolone Acetate | 11 | $299 |
| Fluticasone Propionate | 22 | $227 |
| Ofloxacin | 16 | $167 |
| Mupirocin | 11 | $110 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology/facial plastic surgery in Hannibal
- Justin ImhofHannibal$125
- Richard MaackChesterfield$18K
- Brian HendricksKansas City$6K
- Matthew EricksenBolivar$2K
- Kent McIntireJoplin$987
- Stephen HadfordColumbia$859
- Jonathan BrownSedalia$663
- Kelly BurchettKirksville$554
- Eric BarbariteCreve Coeur$436
- Mark HechlerWarrensburg$326
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.